EMA accepts AstraZeneca’s MAA for gout treatment lesinurad

The European Medicines Agency has accepted AstraZeneca’s marketing authorisation application (MAA) for lesinurad 200mg tablets for the chronic treatment of hyperuricaemia in combination with xanthine oxidase (XO) inhibitors allopurinol or febuxostat in gout patients when additional therapy is warranted.

Category One, Showcase, status, Uncategorized, What's Hot